Skip to main content
    C

    Candel Therapeutics Inc (CADL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.81
    -0.39 (-6.29%)

    Market Cap: $486.37M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Candel Therapeutics Inc (CADL) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Candel Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$38.18M, operating cash flow was -$38.31M and free cash flow was -$38.90M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$21.87M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $48.27M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$125.00K0.0%100.0%-27777.6%-15035.2%
    Dec 2021$125.00K0.0%100.0%-20580.8%-28899.2%
    Dec 2020$125.00K0.0%100.0%-11048.0%-14144.0%
    Dec 2019$125.00KN/A100.0%-7229.6%-6592.0%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$0$0$0$125.00K$125.00K$125.00K$125.00K
    Cost of revenue$0$0$0$0$0$0$6.61M
    Gross profit$0$0$0$125.00K$125.00K$125.00K$125.00K
    Research and development$30.50M$19.31M$24.51M$20.79M$15.18M$8.75M$6.61M
    Operating income-$48.27M-$33.37M-$38.39M-$34.72M-$25.73M-$13.81M-$9.04M
    Net income-$38.18M-$55.18M-$37.94M-$18.79M-$36.12M-$17.68M-$8.24M
    EBITDA-$39.13MN/A-$36.47M-$17.57MN/AN/A-$8.42M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$1.00M$0$0$0$1.78M
    Gross profit$0$0$0-$163.00K$0$0$0-$245.00K$0$0$0$1.46M
    Operating income-$22.98M-$26.75M-$16.28M-$15.75M-$13.21M-$11.18M-$8.13M-$8.14M-$8.76M-$8.57M-$7.90M-$10.32M
    Net income-$21.87M-$38.91M-$8.86M-$29.50M-$11.27M-$4.80M$7.38M-$14.07M-$10.65M-$22.24M-$8.22M-$11.10M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $47.13M by $72.60M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$125.19M$106.87M$41.20M$77.69M$89.20M$38.28M$45.90M
    Current assets$121.39M$103.80M$36.80M$71.94M$84.94M$35.15M$45.21M
    Cash and equivalents$119.73M$102.65M$35.41M$70.06M$82.64M$35.05M$5.18M
    Total liabilities$73.27M$40.54M$28.46M$29.98M$25.07M$12.78M$53.94M
    Short-term debt$0$9.89M$8.89M$0N/A$463.00KN/A
    Long-term debt$47.13M$2.60M$12.38M$20.85M$560.00K$483.00K$420.00K
    Shareholder equity$51.92M$66.33M$12.74M$47.71M$64.14M-$23.56M-$8.04M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$211.11M$208.15M$201.92M$125.19M$93.60M$105.97M$95.91M$106.87M$21.52M$26.48M$31.22M$41.70M
    Total liabilities$79.52M$82.02M$63.89M$73.27M$13.47M$15.76M$21.23M$40.54M$36.77M$36.46M$25.24M$28.96M
    Cash and equivalents$203.12M$201.56M$194.83M$119.73M$86.96M$100.69M$92.17M$102.65M$16.56M$21.45M$25.71M$35.41M
    Shareholder equity$131.59M$126.13M$138.03M$51.92M$80.12M$90.21M$74.67M$66.33M-$15.26M-$9.97M$5.98M$12.74M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$38.31M-$27.02M-$34.24M-$31.42M-$22.22M-$9.07M-$5.18M
    Capital expenditures$587.00K$16.00K$457.00K$1.30M$1.83M$1.48M$159.00K
    Free cash flow-$38.90M-$27.04M-$34.70M-$32.72M-$24.05M-$10.55M-$5.34M
    Investing cash flow-$560.00K-$16.00K-$280.00K-$1.30M-$1.83M$38.45M-$35.74M
    Financing cash flow$56.10M$94.28M-$121.00K$19.97M$71.80M$490.00K$21.98M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$23.12M-$17.18M-$18.04M-$10.57M-$10.24M-$8.89M-$8.62M-$5.81M-$6.57M-$6.20M-$8.44M-$7.42M
    Capital expenditures$141.00K$69.00K$675.00K$409.00K$144.00K$31.00K$3.00K$3.00K$0$6.00K$7.00K$47.00K
    Free cash flow-$23.26M-$17.25M-$18.71M-$10.98M-$10.38M-$8.92M-$8.62M-$5.82M-$6.57M-$6.20M-$8.45M-$7.47M
    Last 12 quarters

    Frequently Asked Questions About CADL

    What is Candel Therapeutics' annual revenue?

    Candel Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Candel Therapeutics profitable?

    No. Candel Therapeutics reported net income of -$38.18M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does CADL generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$38.31M minus capital expenditures of $587.00K produced free cash flow of -$38.90M.

    How much debt does Candel Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $47.13M, short-term debt of $0 and cash and equivalents of $119.73M.